Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Share-based Compensation: 2009-2025

Historic Share-based Compensation for Myriad Genetics (MYGN) over the last 16 years, with Sep 2025 value amounting to $12.2 million.

  • Myriad Genetics' Share-based Compensation fell 1.61% to $12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.3 million, marking a year-over-year decrease of 12.17%. This contributed to the annual value of $49.8 million for FY2024, which is 22.36% up from last year.
  • According to the latest figures from Q3 2025, Myriad Genetics' Share-based Compensation is $12.2 million, which was up 14.02% from $10.7 million recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' Share-based Compensation ranged from a high of $14.5 million in Q2 2024 and a low of $7.5 million during Q1 2023.
  • Moreover, its 3-year median value for Share-based Compensation was $11.2 million (2023), whereas its average is $11.2 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first crashed by 43.62% in 2021, then skyrocketed by 60.00% in 2024.
  • Over the past 5 years, Myriad Genetics' Share-based Compensation (Quarterly) stood at $8.4 million in 2021, then fell by 2.38% to $8.2 million in 2022, then grew by 26.83% to $10.4 million in 2023, then rose by 4.81% to $10.9 million in 2024, then dropped by 1.61% to $12.2 million in 2025.
  • Its last three reported values are $12.2 million in Q3 2025, $10.7 million for Q2 2025, and $9.5 million during Q1 2025.